Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk

Area of Science:

• Cardiovascular Science
• Inflammation Biology
• Pharmacology

Background:

• Cyclooxygenase-2 (COX-2) is implicated in inflammation, pain, and physiological functions in tissues like the kidney and endothelium.
• The precise role of COX-2 in atherosclerosis remains unclear, despite existing evidence.
• Clinical trials of selective COX-2 inhibitors have indicated a potential increase in cardiovascular risk.

Purpose of the Study:

• To review the expression patterns of COX-2 in atherothrombosis.
• To elucidate the role of COX-2 in determining plaque vulnerability.
• To examine the vascular effects of prostanoid inhibition by COX-2 inhibitors.

Main Methods:

• Review of existing literature on COX-2 expression in cardiovascular disease.
• Analysis of data from clinical trials concerning selective COX-2 inhibitors.
• Examination of the molecular mechanisms linking COX-2 to atherothrombosis.

Main Results:

• COX-2 is expressed in key cellular components of atherothrombosis.
• COX-2 activity influences atherosclerotic plaque stability and vulnerability.
• Selective COX-2 inhibition affects vascular prostanoid synthesis and may increase cardiovascular risk.

Conclusions:

• The role of COX-2 in atherosclerosis is complex and warrants further investigation.
• The cardiovascular risks associated with selective COX-2 inhibitors necessitate careful consideration.
• Understanding COX-2's vascular effects is crucial for developing safer anti-inflammatory therapies.